Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model
The sustainability/stability of Sipai’s performance/growth potential is worrying. Weak profitability make Sipai hard to be breakeven.High valuation...
289 Views
Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?
PAGD's intention to improve profitability at the expense of revenue scale is obvious. Switching from 2C to 2B model is a double-edged sword....
369 Views
Pre-IPO Fangzhou Group - The Business and the Concerns
The 2C model of online medical care is hard to achieve large-scale profit. 2B is a breakthrough point. But Fangzhou has no perfect solution to...
352 Views
Fangzhou Pre-IPO - The Negatives - Hard to Shake off Loss-Making Tendencies
Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO. In this note, we will talk about the not-so-positive...
464 Views
Fangzhou Pre-IPO - The Positives - Regulatory Changes and COVID Spurred Growth
Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO. In this note, we will talk about the positive aspects...
375 Views